Equities research analysts expect that Atossa Genetics Inc (NASDAQ:ATOS) will post earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atossa Genetics’ earnings. Atossa Genetics reported earnings per share of ($2.05) in the same quarter last year, which would suggest a positive year over year growth rate of 76.6%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Atossa Genetics will report full-year earnings of ($4.08) per share for the current fiscal year. For the next year, analysts anticipate that the business will post earnings of ($1.81) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Atossa Genetics.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, August 13th. The company reported ($2.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($2.53).

ATOS has been the topic of several research reports. ValuEngine upgraded shares of Atossa Genetics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Maxim Group reiterated a “buy” rating and issued a $7.00 price target on shares of Atossa Genetics in a research report on Thursday, October 11th.

Shares of NASDAQ ATOS opened at $1.50 on Wednesday. Atossa Genetics has a fifty-two week low of $1.41 and a fifty-two week high of $19.08.

About Atossa Genetics

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

See Also: Stock Selection – What is cash flow?

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.